In MM, the PI3K/Akt/mTOR pathway is overexpressed,(64,80,83) inhibition of the activity of certain pathway components, such as PI3Kand mTOR, being therefore an excellent therapeutic pathway.(84) However, the applicability of such drugs in clinical practice has provedfrustrating.(85). The gene discussed is AKT1; the disease is Miyoshi myopathy.